0057
View Abstract / View Presentation
Multiparametric MRI signatures of immune response in patients with HER2+ breast cancer treated with trastuzumab
Bonny Chau1, Debosmita Biswas1, Anum S. Kazerouni1, Daniel S. Hippe1, Rebeca Alvarez1, Suzanne Dintzis1, Laura C. Kennedy2, Vijayakrishna Gadi3, and Savannah C. Partridge 1
1University of Washington, Seattle, WA, United States, 2Vanderbilt University, Nashville, TN, United States, 3University of Illinois, Chicago, IL, United States
In patients with HER2+ breast cancer treated with trastuzumab, pre-treatment ADC on DW-MRI and change in peak percent enhancement on DCE-MRI were significantly associated with immune response.
Figure 3. Example cases